Cargando…

Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study

BACKGROUND: Hydroxyurea prevents disease complications among patients with sickle cell disease (SCD). Although its efficacy has been endorsed by the National Health Lung and Blood Institute evidence-based guidelines, its adoption is low, both by patients with SCD and providers. Mobile health (mHealt...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hankins, Jane S, Shah, Nirmish, DiMartino, Lisa, Brambilla, Donald, Fernandez, Maria E, Gibson, Robert W, Gordeuk, Victor R, Lottenberg, Richard, Kutlar, Abdullah, Melvin, Cathy, Simon, Jena, Wun, Ted, Treadwell, Marsha, Calhoun, Cecelia, Baumann, Ana, Potter, Michael B, Klesges, Lisa, Bosworth, Hayden
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	JMIR Publications 2020
Materias:	Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7388044/ https://www.ncbi.nlm.nih.gov/pubmed/32442144 http://dx.doi.org/10.2196/16319

Ejemplares similares

Evaluating the implementation of a multi-level mHealth study to improve hydroxyurea utilization in sickle cell disease
por: Hankins, J. S, et al.
Publicado: (2023)

Impact of the COVID-19 Pandemic on the Implementation of Mobile Health to Improve the Uptake of Hydroxyurea in Patients With Sickle Cell Disease: Mixed Methods Study
por: Badawy, Sherif M, et al.
Publicado: (2022)

Implementation and Preliminary Effectiveness of mHealth Apps for Improving Sickle Cell Disease Care during COVID-19: A Mixed-Methods Evaluation
por: Badawy, Sherif M., et al.
Publicado: (2021)

Burden of Aging: Health Outcomes Among Adolescents and Young Adults With Sickle Cell Disease
por: Howell, Kristen E., et al.
Publicado: (2023)

Identifying barriers to evidence-based care for sickle cell disease: results from the Sickle Cell Disease Implementation Consortium cross-sectional survey of healthcare providers in the USA
por: Smeltzer, Matthew P, et al.
Publicado: (2021)

Examining Mental Health, Education, Employment, and Pain in Sickle Cell Disease
por: Harris, Kelly M., et al.
Publicado: (2023)

Hydroxyurea Use After Transitions of Care Among Young Adults With Sickle Cell Disease and Tennessee Medicaid Insurance
por: Mathias, Joacy G., et al.
Publicado: (2021)

Sex-based differences in the manifestations and complications of sickle cell disease: Report from the Sickle Cell Disease Implementation Consortium
por: Masese, Rita V., et al.
Publicado: (2021)

An evaluation of patient-reported outcomes in sickle cell disease within a conceptual model
por: Treadwell, Marsha J., et al.
Publicado: (2022)

Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: Report from a U.S. regional collaborative
por: Treadwell, Marsha J., et al.
Publicado: (2022)

Perceptions of US Adolescents and Adults With Sickle Cell Disease on Their Quality of Care
por: Kanter, Julie, et al.
Publicado: (2020)

Perspectives of individuals with sickle cell disease on barriers to care
por: Phillips, Shannon, et al.
Publicado: (2022)

Development of the InCharge Health Mobile App to Improve Adherence to Hydroxyurea in Patients With Sickle Cell Disease: User-Centered Design Approach
por: Alberts, Nicole M, et al.
Publicado: (2020)

Hydroxyurea differentially modulates activator and repressors of γ-globin gene in erythroblasts of responsive and non-responsive patients with sickle cell disease in correlation with Index of Hydroxyurea Responsiveness
por: Zhu, Xingguo, et al.
Publicado: (2017)

Electronic Health Record–Embedded Individualized Pain Plans for Emergency Department Treatment of Vaso-occlusive Episodes in Adults With Sickle Cell Disease: Protocol for a Preimplementation and Postimplementation Study
por: Luo, Lingzi, et al.
Publicado: (2021)

What does it mean to be affiliated with care?: Delphi consensus on the definition of “unaffiliation” and “specialist” in sickle cell disease
por: Lamont, Andrea E., et al.
Publicado: (2022)

Publication of data collection forms from NHLBI funded sickle cell disease implementation consortium (SCDIC) registry
por: Glassberg, Jeffrey A., et al.
Publicado: (2020)

Hydroxyurea Use and Hospitalization Trends in a Comprehensive Pediatric Sickle Cell Program
por: Nottage, Kerri A., et al.
Publicado: (2013)

Engaging Caregivers and Providers of Children With Sickle Cell Anemia in Shared Decision Making for Hydroxyurea: Protocol for a Multicenter Randomized Controlled Trial
por: Hood, Anna M, et al.
Publicado: (2021)

Intensive hydroxyurea dosing in very young children with sickle cell anemia
por: Wang, Winfred C., et al.
Publicado: (2023)

From Infancy to Adolescence: Fifteen Years of Continuous Treatment With Hydroxyurea in Sickle Cell Anemia
por: Hankins, Jane S., et al.
Publicado: (2014)

Hydroxyurea Treatment for Sickle Cell Disease
por: Steinberg, Martin H.
Publicado: (2002)

Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study
por: Shah, Nirmish, et al.
Publicado: (2019)

A Retrospective Review to Determine If Children with Sickle Cell Disease Receive Hydroxyurea Monitoring
por: Creary, Susan E., et al.
Publicado: (2017)

A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study
por: Creary, Susan, et al.
Publicado: (2019)

Hydroxyurea and sickle cell anemia: effect on quality of life
por: Ballas, Samir K, et al.
Publicado: (2006)

Effective control of sickle cell disease with hydroxyurea therapy
por: Singh, Harminder, et al.
Publicado: (2010)

The influence of hydroxyurea on oxidative stress in sickle cell anemia
por: Torres, Lidiane de Souza, et al.
Publicado: (2012)

Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease
por: de Oliveira, Emanuel Almeida Moreira, et al.
Publicado: (2019)

ENHANCE—(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease
por: Creary, Susan, et al.
Publicado: (2016)

The role of hydroxyurea to prevent silent stroke in sickle cell disease: Systematic review and meta-analysis
por: Hasson, Carla, et al.
Publicado: (2019)

Metabolic signatures of cardiorenal dysfunction in plasma from sickle cell patients as a function of therapeutic transfusion and hydroxyurea treatment
por: D’Alessandro, Angelo, et al.
Publicado: (2023)

The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea
por: da Silva, Luiz Bernardino Lima, et al.
Publicado: (2012)

Comment on "The influence of hydroxyurea on oxidative stress in sickle cell anemia"
por: van Beers, Eduard Johannes, et al.
Publicado: (2012)

Emerging Science of Hydroxyurea Therapy for Pediatric Sickle Cell Disease
por: Green, Nancy S., et al.
Publicado: (2013)

Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia
por: Keikhaei, Bijan, et al.
Publicado: (2016)

Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease
por: Wong, Trisha E., et al.
Publicado: (2021)

Mathematical Modeling of Hydroxyurea Therapy in Individuals with Sickle Cell Disease
por: Pandey, Akancha, et al.
Publicado: (2022)

Hydroxyurea treatment for adult sickle cell anemia patients in Kinshasa
por: Kabuyi, Paul Lumbala, et al.
Publicado: (2023)

Comment on "The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea"
por: Souza, José Carlos, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_nrovvtrnc3t5pu80jkn86irkbj